IL145526A0 - Compositions and methods for effecting the levels of high density lipoprotein (hdl) chloesterol and apolipoprotein ai, very low density lipopritein (vldl) cholesterol and low density lipoprotein (ldl) cholesterol - Google Patents

Compositions and methods for effecting the levels of high density lipoprotein (hdl) chloesterol and apolipoprotein ai, very low density lipopritein (vldl) cholesterol and low density lipoprotein (ldl) cholesterol

Info

Publication number
IL145526A0
IL145526A0 IL14552600A IL14552600A IL145526A0 IL 145526 A0 IL145526 A0 IL 145526A0 IL 14552600 A IL14552600 A IL 14552600A IL 14552600 A IL14552600 A IL 14552600A IL 145526 A0 IL145526 A0 IL 145526A0
Authority
IL
Israel
Prior art keywords
cholesterol
low density
density lipoprotein
lipopritein
chloesterol
Prior art date
Application number
IL14552600A
Original Assignee
Aventis Pharm Prod Inc
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/277,401 external-priority patent/US7008776B1/en
Application filed by Aventis Pharm Prod Inc, Univ Pennsylvania filed Critical Aventis Pharm Prod Inc
Publication of IL145526A0 publication Critical patent/IL145526A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Plant Substances (AREA)
IL14552600A 1999-03-26 2000-03-24 Compositions and methods for effecting the levels of high density lipoprotein (hdl) chloesterol and apolipoprotein ai, very low density lipopritein (vldl) cholesterol and low density lipoprotein (ldl) cholesterol IL145526A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/277,401 US7008776B1 (en) 1996-12-06 1999-03-26 Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol
PCT/US2000/007870 WO2000057837A2 (en) 1999-03-26 2000-03-24 Compositions and methods for effecting the levels of cholesterol

Publications (1)

Publication Number Publication Date
IL145526A0 true IL145526A0 (en) 2002-06-30

Family

ID=23060703

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14552600A IL145526A0 (en) 1999-03-26 2000-03-24 Compositions and methods for effecting the levels of high density lipoprotein (hdl) chloesterol and apolipoprotein ai, very low density lipopritein (vldl) cholesterol and low density lipoprotein (ldl) cholesterol
IL145526A IL145526A (en) 1999-03-26 2001-09-20 Method for diagnosing predispositions to low hdl cholesterol and apolipoprotein ai and method for determining inhibition of enzymotic reaction between lipg and hdl or vldl or ldl

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL145526A IL145526A (en) 1999-03-26 2001-09-20 Method for diagnosing predispositions to low hdl cholesterol and apolipoprotein ai and method for determining inhibition of enzymotic reaction between lipg and hdl or vldl or ldl

Country Status (13)

Country Link
EP (1) EP1171078A4 (en)
JP (1) JP2002540127A (en)
KR (2) KR20050044812A (en)
AU (1) AU776684B2 (en)
BR (1) BR0009333A (en)
CA (1) CA2363486C (en)
HK (1) HK1043309A1 (en)
IL (2) IL145526A0 (en)
MX (1) MXPA01009727A (en)
NO (2) NO331779B1 (en)
NZ (2) NZ531180A (en)
WO (1) WO2000057837A2 (en)
ZA (1) ZA200107598B (en)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507808B2 (en) * 2002-12-12 2009-03-24 Isis Pharmaceuticals, Inc. Modulation of endothelial lipase expression
EP1976567B1 (en) 2005-12-28 2020-05-13 The Scripps Research Institute Natural antisense and non-coding rna transcripts as drug targets
EP2370581B1 (en) 2008-12-04 2016-08-03 CuRNA, Inc. Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf
CN107338251A (en) 2008-12-04 2017-11-10 库尔纳公司 It is diseases related that natural antisense transcript by suppressing tumor suppressor gene treats tumor suppressor gene
JP6091752B2 (en) 2008-12-04 2017-03-08 クルナ・インコーポレーテッド Treatment of erythropoietin (EPO) -related diseases by suppression of natural antisense transcripts against EPO
HUE026280T2 (en) 2009-02-12 2016-06-28 Curna Inc Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
JP6116242B2 (en) 2009-03-16 2017-04-19 クルナ・インコーポレーテッド Treatment of NRF2-related diseases by suppression of natural antisense transcripts against nuclear factor (erythrocyte-derived 2) -like 2 (NRF2)
JP5904935B2 (en) 2009-03-17 2016-04-20 クルナ・インコーポレーテッド Treatment of DLK1-related diseases by suppression of natural antisense transcripts against Delta-like 1 homolog (DLK1)
CN103223177B (en) 2009-05-06 2016-08-10 库尔纳公司 By suppression therapy lipid transfer and the metabolic gene relevant disease of the natural antisense transcript for lipid transfer and metabolic gene
WO2010129746A2 (en) 2009-05-06 2010-11-11 Curna, Inc. Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp
CA3185821A1 (en) 2009-05-08 2010-11-11 Curna, Inc. Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family
EP2432881B1 (en) 2009-05-18 2017-11-15 CuRNA, Inc. Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
KR101703695B1 (en) 2009-05-22 2017-02-08 큐알엔에이, 인크. Treatment of transcription factor e3 (tfe3) and insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to tfe3
KR20120024819A (en) 2009-05-28 2012-03-14 오피케이오 큐알엔에이, 엘엘씨 Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
KR101702689B1 (en) 2009-06-16 2017-02-06 큐알엔에이, 인크. Treatment of paraoxonase 1 (pon1) related diseases by inhibition of natural antisense transcript to pon1
ES2620960T3 (en) 2009-06-16 2017-06-30 Curna, Inc. Treatment of diseases related to a collagen gene by inhibiting a natural antisense transcript to a collagen gene
CA2765889A1 (en) 2009-06-24 2010-12-29 Opko Curna, Llc Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2
KR101807324B1 (en) 2009-06-26 2017-12-08 큐알엔에이, 인크. Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
US20120252869A1 (en) 2009-07-24 2012-10-04 Opko Curna, Llc Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
ES2585360T3 (en) 2009-08-05 2016-10-05 Curna, Inc. Treatment of diseases related to an insulin gene (INS) by inhibition of natural antisense transcription in an insulin gene (INS)
KR101827015B1 (en) 2009-08-11 2018-02-07 큐알엔에이, 인크. Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq)
CN102482670B (en) 2009-08-21 2018-06-15 库尔纳公司 CHIP relevant diseases are treated by inhibiting the natural antisense transcript of ' C-terminal of HSP70- interaction proteins ' (CHIP)
WO2011031482A2 (en) 2009-08-25 2011-03-17 Curna, Inc. Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap
US20120295952A1 (en) 2009-09-25 2012-11-22 Curna, Inc. Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity
JP6025567B2 (en) 2009-12-16 2016-11-16 カッパーアールエヌエー，インコーポレイテッド Treatment of MBTPS1-related diseases by inhibition of the natural antisense transcript against the membrane-bound transcription factor peptidase, site 1 (MBTPS1)
WO2011079261A2 (en) 2009-12-23 2011-06-30 Curna, Inc. Treatment of hepatocyte growth factor (hgf) related diseases by inhibition of natural antisense transcript to hgf
RU2619185C2 (en) 2009-12-23 2017-05-12 Курна, Инк. Treatment of diseases associated with uncoupling proteins 2 (ucp2), by inhibiting of natural antisense transcript to ucp2
CA2785173A1 (en) 2009-12-29 2011-07-28 Curna, Inc. Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1
JP5982288B2 (en) 2009-12-29 2016-08-31 カッパーアールエヌエー，インコーポレイテッド Treatment of tumor protein 63-related diseases by inhibition of natural antisense transcripts against tumor protein 63 (p63)
ES2677044T3 (en) 2009-12-31 2018-07-27 Curna, Inc. Treatment of diseases related to insulin receptor substrate 2 (IRS2) by inhibition of natural antisense transcript for IRS2 and transcription factor E3 (TFE3)
NO2521784T3 (en) 2010-01-04 2018-05-05
RU2612161C2 (en) 2010-01-06 2017-03-02 Курна, Инк. Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to pancreatic developmental gene
ES2664866T3 (en) 2010-01-11 2018-04-23 Curna, Inc. Treatment of diseases related to sex hormone binding globulin (shbg) by inhibition of the natural antisense transcript to shbg
CN102782135A (en) 2010-01-25 2012-11-14 库尔纳公司 Treatment of RNase H1 related diseases by inhibition of natural antisense transcript to RNase H1
KR101838308B1 (en) 2010-02-22 2018-03-13 큐알엔에이, 인크. Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
CA2795145C (en) 2010-04-02 2019-01-22 Curna, Inc. Treatment of colony-stimulating factor 3 (csf3) related diseases by inhibition of natural antisense transcript to csf3
EP3517613A1 (en) 2010-04-09 2019-07-31 CuRNA, Inc. Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21
US9089588B2 (en) 2010-05-03 2015-07-28 Curna, Inc. Treatment of sirtuin (SIRT) related diseases by inhibition of natural antisense transcript to a sirtuin (SIRT)
TWI586356B (en) 2010-05-14 2017-06-11 可娜公司 Treatment of par4 related diseases by inhibition of natural antisense transcript to par4
EP2576783B1 (en) 2010-05-26 2017-11-29 CuRNA, Inc. Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1
EP2576784B1 (en) 2010-05-26 2017-11-15 CuRNA, Inc. Treatment of methionine sulfoxide reductase a (msra) related diseases by inhibition of natural antisense transcript to msra
PT2585596T (en) 2010-06-23 2021-03-23 Curna Inc Treatment of sodium channel, voltage-gated, alpha subunit (scna) related diseases by inhibition of natural antisense transcript to scna
NO2593547T3 (en) 2010-07-14 2018-04-14
WO2012047956A2 (en) 2010-10-06 2012-04-12 Opko Curna Llc Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4
CN103180445B (en) 2010-10-22 2018-02-16 库尔纳公司 IDUA relevant diseases are treated by suppressing the natural antisense transcript of α L iduronases (IDUA)
US10000752B2 (en) 2010-11-18 2018-06-19 Curna, Inc. Antagonat compositions and methods of use
JP6071893B2 (en) 2010-11-23 2017-02-01 カッパーアールエヌエー，インコーポレイテッド Treatment of NANOG-related diseases by inhibition of natural antisense transcripts to NANOG
CN103620036B (en) 2011-06-09 2016-12-21 库尔纳公司 FXN relevant disease is treated by the natural antisense transcript of suppression Frataxin (FXN)
CN108272782B (en) 2011-09-06 2021-04-23 库尔纳公司 Use of small molecules in preparation of medicine for treating Dravet syndrome or generalized epilepsy with febrile convulsion adjunctive disease
ES2694592T3 (en) 2012-03-15 2018-12-21 Curna, Inc. Treatment of diseases related to brain-derived neurotrophic factor (BDNF) by inhibition of the natural antisense transcript of BDNF
CN102628060A (en) * 2012-03-22 2012-08-08 北京济福霖生物技术有限公司 Production method of low-fat milk
US9695462B2 (en) 2012-11-05 2017-07-04 Shionogi & Co., Ltd. Method for evaluation of drug efficacy of a medicine having a therapeutic or preventive effect against a disease related to EL activity and a method for screening an inhibitor of EL activity
BR112015022009A2 (en) 2013-03-14 2017-08-29 Shionogi & Co MONOCLONAL ANTIBODY, INHIBITING THE ENZYME ACTIVITY OF VASCULAR ENDOTHELIAL LIPASE
TWI688575B (en) 2014-09-11 2020-03-21 日商塩野義製藥股份有限公司 Humanized monoclonal antibody, inhibiting the enzymatic activity of vascular endothelial lipase
MX2023008826A (en) 2021-02-01 2023-09-15 Regenxbio Inc Gene therapy for neuronal ceroid lipofuscinoses.
JPWO2023008337A1 (en) * 2021-07-26 2023-02-02

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0707638A4 (en) * 1992-12-04 1998-05-20 Innovir Lab Inc Regulatable nucleic acid therapeutic and methods of use thereof
DE948609T1 (en) * 1996-12-06 2000-03-09 Rhone Poulenc Rorer Pharma POLYPEPTIDES COVERED BY HUMANEM LIPASE-LIKE GENE, COMPOSITIONS AND METHODS
WO1999032611A1 (en) * 1997-12-19 1999-07-01 Progenitor, Inc. A lipase expressed in endothelial cells and methods for its use

Also Published As

Publication number Publication date
HK1043309A1 (en) 2002-09-13
CA2363486C (en) 2012-12-18
IL145526A (en) 2010-11-30
AU776684B2 (en) 2004-09-16
ZA200107598B (en) 2003-05-28
NZ514350A (en) 2004-12-24
NO20100214L (en) 2001-11-21
NO20014657L (en) 2001-11-21
EP1171078A2 (en) 2002-01-16
KR20020029651A (en) 2002-04-19
WO2000057837A2 (en) 2000-10-05
BR0009333A (en) 2002-01-08
JP2002540127A (en) 2002-11-26
KR100887164B1 (en) 2009-03-10
EP1171078A4 (en) 2002-11-06
WO2000057837A3 (en) 2001-01-25
AU3918700A (en) 2000-10-16
CA2363486A1 (en) 2000-10-05
MXPA01009727A (en) 2002-07-22
WO2000057837A8 (en) 2001-09-27
NO331784B1 (en) 2012-03-26
NO331779B1 (en) 2012-03-26
WO2000057837A9 (en) 2001-10-18
KR20050044812A (en) 2005-05-12
NO20014657D0 (en) 2001-09-25
NZ531180A (en) 2005-06-24

Similar Documents

Publication Publication Date Title
IL145526A0 (en) Compositions and methods for effecting the levels of high density lipoprotein (hdl) chloesterol and apolipoprotein ai, very low density lipopritein (vldl) cholesterol and low density lipoprotein (ldl) cholesterol
EE200300136A (en) Compositions and methods for lowering plasma lipoprotein (a) levels and reducing risk factors for cardiovascular disease
EP1212065A4 (en) Compositions and methods for raising hdl cholesterol levels
HU0100388D0 (en) Pharmaceutical compositions and methods for treating osteoporosis and lowering cholesterol
AU2002306930A1 (en) Plasma processor and method for operating same
AU1856997A (en) Method for raising hdl cholesterol levels
IL112593A0 (en) Methods for inhibiting bone loss and lowering serum cholesterol
EP1292603B8 (en) Methods and compositions for treating hepatitis c virus
MY121405A (en) 4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinolines
MY130670A (en) 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
MY121838A (en) 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
AU1296099A (en) Methods and compositions for treating dermatoses
AU4446400A (en) Method and apparatuses for plasma treatment
AU2003204024A1 (en) Methods for quantitating high-density lipoprotein cholesterol
AU6274898A (en) Bipolar vaporization apparatus and method for arthroscopy
AU2002221657A1 (en) Method and system for preventing the spread of computer viruses
DE69931279D1 (en) METHOD AND COMPOSITIONS FOR REDUCING THE CHOLESTEROL MIRROR IN PLASMA
AU3065999A (en) Compositions and methods for treatment of asthma
AU3471400A (en) Compositions and methods for controlled delivery of virus vectors
AU3074099A (en) Method and composition for lowering low density lipoprotein cholesterol
AU2001268601A1 (en) Methods and apparatus for reducing vibrations induced within fan assemblies
AU7589598A (en) Elevation of hdl cholesterol by 2-(4-chloro -1-aryl-butylidene) -hydrazinecarbothioamides
EP1089731A4 (en) Compositions and methods for treating elevated blood cholesterol
AU4558799A (en) Methods and compositions for generating recombinant adeno-associated virus vectors
AU2001243614A1 (en) Phosphatidylcholine compositions and methods for lowering intestinal absorption and plasma levels of cholesterol